PMID- 37542197
OWN - NLM
STAT- MEDLINE
DCOM- 20230922
LR  - 20230922
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
VI  - 47
IP  - 10
DP  - 2023 Oct
TI  - Glucose metabolism disorder: a potential accomplice of SARS-CoV-2.
PG  - 893-902
LID - 10.1038/s41366-023-01352-y [doi]
AB  - Globally, 265,713,467 confirmed cases of SARS-CoV-2 (CoV-2), including 5,260,888 
      deaths, have been reported by the WHO. It is important to study the mechanism of 
      this infectious disease. A variety of evidences show the potential association 
      between CoV-2 and glucose metabolism. Notably, people with type 2 diabetes 
      mellitus (T2DM) and other metabolic complications were prone to have a higher 
      risk of developing a more severe infection course than people who were 
      metabolically normal. The correlations between glucose metabolism and CoV-2 
      progression have been widely revealed. This review will discuss the association 
      between glucose metabolism disorders and CoV-2 progression, showing the promoting 
      effect of diabetes and other diseases related to glucose metabolism disorders on 
      the progression of CoV-2. We will further conclude the effects of key proteins 
      and pathways in glucose metabolism regulation on CoV-2 progression and potential 
      interventions by targeting glucose metabolism disorders for CoV-2 treatment. 
      Therefore, this review will provide systematic insight into the treatment of 
      CoV-2 from the perspective of glucose metabolism.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Limited.
FAU - Luan, Yi
AU  - Luan Y
AUID- ORCID: 0000-0002-2511-0359
AD  - Department of Translational Medicine Center, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, 450052, China.
FAU - Luan, Ying
AU  - Luan Y
AD  - State Key Laboratory for Artificial Microstructures and Mesoscopic Physics, 
      School of Physics, Peking University, Beijing, 100000, China.
FAU - He, Hongbo
AU  - He H
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, 450001, China.
FAU - Jue, Bolin
AU  - Jue B
AD  - School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453000, 
      China.
FAU - Yang, Yang
AU  - Yang Y
AUID- ORCID: 0000-0001-7432-4735
AD  - Department of Translational Medicine Center, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, 450052, China. yangyangbio@163.com.
FAU - Qin, Bo
AU  - Qin B
AUID- ORCID: 0009-0000-6056-3698
AD  - Department of Translational Medicine Center, the First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, 450052, China. boqin@mail.ustc.edu.cn.
FAU - Ren, Kaidi
AU  - Ren K
AUID- ORCID: 0000-0002-2011-6743
AD  - Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, 450052, China. renkd006@163.com.
AD  - Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, 
      Zhengzhou, 450052, China. renkd006@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230804
PL  - England
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Humans
MH  - SARS-CoV-2
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *COVID-19/complications
MH  - Glucose
EDAT- 2023/08/05 05:42
MHDA- 2023/09/22 06:42
CRDT- 2023/08/04 23:28
PHST- 2023/04/04 00:00 [received]
PHST- 2023/07/14 00:00 [accepted]
PHST- 2023/06/29 00:00 [revised]
PHST- 2023/09/22 06:42 [medline]
PHST- 2023/08/05 05:42 [pubmed]
PHST- 2023/08/04 23:28 [entrez]
AID - 10.1038/s41366-023-01352-y [pii]
AID - 10.1038/s41366-023-01352-y [doi]
PST - ppublish
SO  - Int J Obes (Lond). 2023 Oct;47(10):893-902. doi: 10.1038/s41366-023-01352-y. Epub 
      2023 Aug 4.